DIRS.INFO The most relevant business & tech news

☆ Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
▼ + stars: | 2024-04-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Tirzepatide is the active ingredient in both Eli Lilly's diabetes treatment Mounjaro and its anti-obesity drug Zepbound. Based on that calculation, earnings will be lower by about 13 cents per share, he said, in research published last Tuesday. "Strong demand for Mounjaro & Zepbound can easily pull through in 2H24 and make up for any 1H24 shortfalls." For the week ended April 19, combined prescriptions of Mounjaro and Zepbound rose 63% year over year, according to IQVIA. Wells Fargo Mohit Bansal said he expects investors to look past any Trulicity shortfalls as the focus is firmily on Zepbound and Mounjaro for Lilly's future growth.

Persons: Eli Lilly, Eli, James Shin, Lilly, Shin, David Risinger, Zepbound, Wells, Bansal, Jo Walton, Walton, Lilly's, Tirzepatide, Deutsche Bank's Shin, — CNBC's Michael Bloom Organizations: Drug Administration, Deutsche Bank, IMS, UBS, Research, Deutsche, FDA Locations: 2H24, U.S

Morgan Stanley raised its price target on Nvidia, calling for more than 15% upside going forward. — Lisa Kailai Han 5:53 a.m.: Jefferies lowers Tesla price target, cites 'self-inflicted' wounds Tesla's troubles may not be over yet, according to Jefferies. The investment firm kept its hold rating on the electric vehicle maker and lowered its price target to $165 from $185. Jefferies analyst Philippe Houchois also said Tesla is plagued by shifting product priorities. — Lisa Kailai Han 5:53 a.m.: Morgan Stanley raises Nvidia price target Nvidia has already rallied more than 72% in 2024.

Persons: Morgan Stanley, Jefferies, Patrick Cunningham, Erik Fyrwald's, Cunningham, — Lisa Kailai Han, Zillow, John Colantuoni, Colantuoni, Scott Schoenhaus, Schoenhaus, Lisa Kailai Han, Hess, Betty Jiang, CVX, Jiang, Tesla, Philippe Houchois, Joseph Moore, Moore, — Fred Imbert Organizations: CNBC, Nvidia, Citi, Management, & Biosciences, Jefferies, National Association of Realtors, Markets, GDRX, Barclays, Chevron, NVIDIA, AMD Locations: Tuesday's, China

☆ Wells Fargo hikes S&P 500 year-end target to 5,535, says 'melt-up' in second half likely
▼ + stars: | 2024-04-08 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Expect the stock market's run to record highs to continue as the year goes on, according to Wells Fargo. Christopher Harvey, the bank's head of equity strategy, raised his 2024 S & P 500 target to 5,535 from 4,625, implying a 6.4% upside from here. Wells Fargo' new forecast is one of the highest on the Street, surpassing the 5,500 target from John Stoltzfus at Oppenheimer. .SPX 1Y mountain S & P 500 The market's 2024 took a breather as of late as investors reassessed the Federal Reserve's path to cut interest rates. The S & P 500 declined nearly 1% during the period, its biggest weekly loss since early January.

Persons: Christopher Harvey, Harvey, Wells Fargo, John Stoltzfus Organizations: CNBC Pro Market, Survey, Dow Jones Locations: Wells Fargo, Oppenheimer

Oppenheimer increased its price target on Netflix, calling for upside of nearly 20%. Bernstein, meanwhile, reiterated an outperform rating on Taiwan Semiconductor, noting that margins will fare better than the Street expects going forward. Analyst Stephen Grambling downgraded Hyatt to equal weight from overweight and lowered his price target by $7 to $149. — Pia Singh 5:44 a.m.: Bernstein sticking by Taiwan Semiconductor Taiwan Semiconductor shares are off to a strong start for the year, and Bernstein expects them to continue doing well. The firm raised its price target on them to $150 from $125, implying upside of just 2%.

Persons: Oppenheimer, Bernstein, Morgan Stanley downgrades Hyatt, Morgan Stanley, Hyatt's, Stephen Grambling, Grambling, Hyatt, FactSet, — Pia Singh, Oppenheimer Oppenheimer, Jason Helfstein, Helfstein, Wall, Mark Li, Li, TSMC, 4Q23, — Fred Imbert Organizations: CNBC, Netflix, Taiwan Semiconductor, Hyatt, Taiwan Semiconductor Taiwan Semiconductor, GM Locations: 2H24, U.S, Taiwan

☆ Wall Street analysts come out very bullish on this recent sporting goods IPO
▼ + stars: | 2024-02-26 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

Roach is even more bullish than many on Wall Street with a price target of $21 per share. Like many peers on the Street, she sees the company getting a boost from market share growth and an expansion of direct-to-consumer. Multiple analysts deemed Arc'teryx the "crown jewel' of Amer's portfolio. Though Arc'teryx provides a key reason for bullishness, analysts also have their eyes on other well-known brands in the portfolio. "But, the business faces an uncertain 1H24 wholesale backdrop, & comes with single-segment growth & profitability expansion reliance, multi-brand portfolio volatility risk, & high relative leverage levels."

Persons: Wilson, Arc'teryx, FactSet, Goldman Sachs, Brooke Roach, Roach, She's, Amer, Lorraine Hutchinson, Matthew Boss, Paul Lejuez, Salomon, Baird, Jonathan Komp, Amer's, Jay Sole, Morgan Stanley, Alex Straton, Straton Organizations: Amer, New York Stock Exchange, DTC, Bank of America, Amer Sports, Citi, UBS Locations: China

☆ Here are Monday's biggest analyst calls: Netflix, Nvidia, Apple, Meta, Lowe's, Walmart, Target, Pepsi & more
▼ + stars: | 2024-02-12 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

JPMorgan upgrades Lowe's to overweight from neutral JPMorgan said investors should buy the stock ahead of earnings later this month. JPMorgan reiterates Netflix as overweight JPMorgan said it's standing by its overweight rating on shares of Netflix. Loop reiterates Meta as buy Loop raised its price target on the stock to $550 per share from $440. Loop reiterates Alphabet as hold Loop raised its price target on the stock to $155 per share from $140. " UBS reiterates Target as buy UBS says Target shares are "compelling."

Persons: Evercore, it's, wouldn't, Rivian, Piper Sandler, Piper, Jefferies, Willis Towers Watson, URBN, Morgan Stanley downgrades Hershey, Morgan Stanley, Morgan Stanley downgrades XPO, Stifel, Raymond James downgrades, Raymond James, Melius, Roth, Guggenheimer, Guggenheim Organizations: Apple, Barclays, Walmart, EV, JPMorgan, generics, UFC, WWE, Netflix, Citi, Willis, PepsiCo, PEP, LT, UBS, Urban Outfitters, Google, 4Q, Bulls, Target, Bank of America, of America, Bank of America downgrades Duke Energy, Duke Energy, Brands, Nvidia, Deutsche Bank, Industries, Deutsche, SilverBow Resources Locations: U.S, Bank of America downgrades, NWL, Republic, Mohawk

Analyst Oliver Chen also maintained his buy rating for Ulta stock, simultaneously lifting his price target to $580 from $570. Deutsche Bank: Reiterate buy rating and $450 price target, implying 10% upside. Kallo's price target of $300 implies that Tesla stock could rally more than 56% from its Tuesday closing price. Citi analyst Christopher Danely also stood by his buy rating on the stock while lifting his price target to $192 from $136. Analyst Jeffrey Adelson downgraded the company to underweight from equal weight and cut his price target to $6.50 from $7.

Persons: Morgan Stanley, TD Cowen, Ulta, Oliver Chen, ULTA, Chen, — Lisa Kailai Han, Goldman Sachs, Kash Rangan, Baird, Tesla, Ben Kallo, Elon Musk's, Toshiya Hari, Hari, Christopher Danely, Vivek Arya, Danely, Arya, Harlan Sur, Kannan Venkateshwar, Venkateshwar, Eric Sheridan, Sheridan, Justin Post, Ross Sandler, Sandler, Ronald Josey, Josey, Morgan Stanley downgrades, Jeffrey Adelson, Adelson, SOFI, SoFi, Fred Imbert Organizations: CNBC, Google, Microsoft, SoFi Technologies, Deutsche Bank, Citi, Barclays, Tesla, Devices, Wall Street, AMD, Bank of America, Barclays downgrades Verizon Barclays, Verizon, Venkateshwar, Bulls, Morgan Stanley downgrades SoFi Locations: Ulta

☆ This little-known genome editing stock is poised to surge more than 60%, JPMorgan says
▼ + stars: | 2024-01-29 | by ( Pia Singh | ) www.cnbc.com time to read: +3 min

JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from increased market share and a strong gene therapy pipeline. "We see BEAM outperforming our coverage over the mid-term, with current levels being an attractive entry point," the analyst said. The stock is down more than 4% so far this year, and has lost more than 42% over the past 12 months. BEAM 1Y mountain Beam stock. He added that BEAM-302 is "uniquely positioned" as a one-time genetic medicine for AATD, particularly given its success in preclinical trials.

Persons: Eric Joseph, Joseph Organizations: Beam Therapeutics, TAM Locations: U.S, 1H24

☆ JPMorgan says investors wishing for early and aggressive rate cuts will be disappointed
▼ + stars: | 2024-01-23 | by ( Jeff Cox | ) www.cnbc.com time to read: +3 min

Rising geopolitical headwinds and the potential for political turmoil could combine to thwart investors' hopes for the Federal Reserve to enact sharp interest rate cuts this year, according to JPMorgan Chase strategists. Markets have been betting that the Fed likely will start lowering its benchmark short-term borrowing rate by May or even as early as March. JPMorgan's investment team said the calculus could be important for investors as stocks and other asset classes look for direction. In recent days, multiple Fed officials have made remarks insisting that they are in no hurry to start cutting rates. For the full year, traders have gone from a strong chance of six cuts to a coin-flip between five and six.

Persons: Marko Kolanovic, Kolanovic, Raphael Bostic, Christopher Waller, — CNBC's Michael Bloom Organizations: Federal Reserve, Chase, JPMorgan, U.S, Fed, European Central Bank, Atlanta Fed, Federal, Market, Traders, Commerce Department Locations: 1H24

☆ Here are Thursday's biggest analyst calls: Apple, Netflix, Nvidia, Meta, Rivian, Costco, Hertz, Microsoft & more
▼ + stars: | 2024-01-18 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Bank of America upgrades Apple to buy from neutral Bank of America said AI and Vision Pro should drive upside for Apple. Bank of America reiterates Microsoft as buy Bank of America raised its price target on Microsoft to $450 per share from $430. Guggenheim reiterates Target as buy Guggenheim said Target is well positioned in 2024. Bank of America names Harley Davidson a top pick Bank of America said the motorcycle company is well positioned for 2024. " Bank of America reiterates ServiceNow as a top pick Bank of America said the stock remains a top idea for 2024.

Persons: KBW downgrades Charles Schwab, KBW, Mizuho, Robinhood, ., DA Davidson, Baird, Rivian, Wolfe, it's, Wells, it's bullish, Bernstein, Guggenheim, Piper Sandler, Tempur Sealy, TPX, CFRA, Harley Davidson, Oppenheimer, Morgan Stanley, Hertz, ServiceNow, Argus, Salesforce, Mike Blake Organizations: UBS, Netflix, Bank of America, Apple, of America, Nvidia, Semiconductors, Barclays, Red Rock Resorts, Vegas Locals, Microsoft, Guggenheim, Citi, JetBlue, Spirit, Costco, Piper, Palo Alto Networks, Paramount, Nasdaq, Hertz, Blackrock, Amazon, Deutsche Bank, Deutsche, JPMorgan Locations: repurchases, Palo, Palo Alto, Southeast China, 1H24, Los Angeles

Thursday's analyst calls featured an upgrade to a car rental stock and a big downgrade to an airline. The bank also hiked his price target on the tech giant to $225 per share, implying upside of 23%. — Pia Singh 5:36 a.m.: Citi downgrades Spirit Airlines to sell Citi is throwing in the towel on Spirit Airlines . Week to date, Spirit shares are down nearly 60%. Spirit shares were down more than 4% in the premarket.

Persons: Morgan Stanley, Hertz, Andrew Percoco, Percoco, — Pia Singh, Wamsi Mohan, Fred Imbert, Kirk Materne, Materne, Dan Dolev, Dolev, he's, CFRA, Kenneth Leon, Berkshire Hathaway, Leon, Ranjan Sharma, Sharma, bode, Adam Jonas, Jonas, Morgan, Stephen Trent, Trent Organizations: CNBC, flipside, Citi, Spirit Airlines, JetBlue, Bank of America, Apple Bank of America, Apple, Microsoft, ISI, Activision, Activision Blizzard, Mizuho, Fidelity National Information Services, Paramount Global, RedBird Capital, Warner Bros ., Comcast, Paramount's, Showtime, Paramount, JPMorgan, Grab Holdings, Hertz Global Holdings, Jan, Citi downgrades Spirit Airlines, Spirit, Airlines Locations: Berkshire, 1H24, Wednesday's

☆ These factors could lift dividend-paying stocks in the first half of 2024, Barclays says
▼ + stars: | 2024-01-04 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +4 min

The utilities sector suffered so much in 2023, that it's due for a snapback in the new year, according to Barclays. They also made the stocks' dividend payments less attractive compared to the risk-free yields on Treasurys. But now these stocks are priced to move, according to Barclays analyst Nicholas Campanella. "We still like the stock," Barclays said, pointing to upside to consensus earnings per share as one of the factors behind its call. Duke offers a dividend yield of 4.2%, but 12 out of the 20 analysts following the stock rate it a hold, per LSEG.

Persons: Nicholas Campanella, XLU, Campanella, Evergy, — CNBC's Michael Bloom Organizations: Barclays . Utilities, Barclays, SPDR, Fed, Electric Power, Dominion Energy, E Corporation, Duke Energy, Duke Locations: Kansas, Kansas City

☆ Evercore ISI sees big pullback in first half of 2024 as recession ‘materializes’
▼ + stars: | 2023-12-11 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

The market is going to worsen early in 2024 before recovering, according to Evercore ISI. The firm sees the S & P 500 falling in the first half of next year to 3,970 as a "recession materializes and politics [amplify] volatility." An inverted yield curve also portends the start of a recessionary period in the first quarter of 2024, he added. "'Defense Wins Championships' is a consistent theme between [the] last hike and first cut in the recession playbook," said Emanuel. By comparison, the S & P 500 is up 20.1% year to date.

Persons: That's, Julian Emanuel, Emanuel Organizations: ISI

☆ Here are Thursday's biggest analyst calls: Nvidia, Apple, Eli Lilly, Salesforce, Snowflake, Snap, Pinterest and more
▼ + stars: | 2023-11-30 | by ( Michael Bloom | ) www.cnbc.com time to read: +9 min

Jefferies upgrades Pinterest and Snap to buy from hold Jefferies sees growth upside in 2024 for both stocks. " Wolfe upgrades Ally Financial to outperform from peer perform Wolfe said in its upgrade of the financial company that it's well-positioned. "In an environment where the probability of a mild recession or soft landing both appear plausible, we believe ALLY is well positioned to outperform in either scenario and upgrade shares to Outperform." "We continue to believe that Salesforce is on track to become the next quality [growth at a reasonable price] stock." Goldman Sachs reiterates Snowflake as buy Goldman Sachs stood by its buy rating on Snowflake after earnings on Wednesday.

Persons: Berenberg, Eli Lilly, Lilly, Wells, BTIG, Jefferies, Bernstein, Burger, Wolfe, TD Cowen downgrades Okta, Cowen, Stifel, Raymond James, Morgan Stanley, Bilibili, BILI, Baird, Pat Shanahan, Wells Fargo, Salesforce, Goldman Sachs, Snowflake, DUK Organizations: pharma, Nvidia, NVIDIA, Jefferies, SNAP, BK, UBS, Service Corporation, Deutsche Bank, Lattice Semiconductor, Apple, JPMorgan, Nokia, Infineon, Watch, Hewlett Packard Enterprise, Barclays, GE Healthcare, Airbus, Bank of America, Duke Energy, HSBC, Molson Coors Locations: FTCH, North America, China

☆ Here are Tuesday's biggest analyst calls: Apple, Tesla, Microsoft, Rivian, Amazon, Skechers, Block and more
▼ + stars: | 2023-10-10 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Bank of America reiterates Apple as neutral Bank of America said Apple Services is the "next leg of growth." UBS reiterates Skechers as buy UBS said it's standing by its buy rating on shares of the shoe company. JPMorgan reiterates Disney as overweight JPMorgan lowered its price target on the stock to $120 per share from $125 but said it's standing by its overweight rating. Bank of America reiterates Block as buy Bank of America said investors should buy the dip in shares of the company formerly known as Square. Morgan Stanley reiterates Microsoft as overweight Morgan Stanley said it's standing by its overweight rating on Microsoft shares.

Persons: Wells, Wells Fargo, Jefferies, Tesla, it's, Skechers, Daiwa, JPMorgan downgrades Corning, JPMorgan, TD Cowen, O'Reilly, Cowen, Morgan Stanley Organizations: UBS, Bank of America, Apple, of America, Apple Services, Google, DOJ, Citi, Huawei, JPMorgan, Disney, ESPN, Arts, EA, " Bank of America, Trust, Northern Trust, Holdings, Juniper Networks, Enterprise, Microsoft Locations: North America, China, Hulu, Juniper, Corning

☆ UBS thinks this residential solar stock can gain more than 50%
▼ + stars: | 2023-10-02 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

UBS thinks it's time for investors to buy Sunnova Energy . Analyst William Grippin initiated coverage of the residential solar company with a buy rating and a $16 price target, which implies shares could gain 52.8% from Friday's close. Sunnova shares have struggled over the past year, losing more than 50%. The federal government provides ITC, or investment tax credits , to advance solar energy adoption through efforts that offset the upfront costs of solar installations, making solar energy more accessible for businesses and individuals. "However, on a 12-mo forward view, the residential solar market looks set for a recovery by 2H24, particularly if consumer funding costs ease."

Persons: William Grippin, Grippin, Sunnova, — CNBC's Michael Bloom Organizations: UBS, Sunnova Energy, NOVA, ITC Locations: Friday's, 1H24

☆ This little-known biotech stock has 'blockbuster potential,' says Citi
▼ + stars: | 2023-09-05 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

Autoimmune disease drugmaker Cabaletta Bio could soon have a multibillion-dollar product on its hands, according to Citi. Analyst Samantha Semenkow initiated research coverage with a buy rating on Cabaletta shares. Last October, the biotech firm obtained an exclusive, worldwide license for its autoimmune disease therapy CABA-201. The treatment is a CD19-directed chimeric antigen receptor modified T-cell therapy (CART), a treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma. "In our view, the risk/reward is favorable into initial CABA-201 clinical data in 1H24."

Persons: Samantha Semenkow, Semenkow, Cabaletta, Morgan Stanley, Cowen, — CNBC's Michael Bloom Organizations: Citi, Evercore ISI Locations: 1H24

☆ Barclays says buy this under-the-radar clean energy stock set to grow revenue 40%
▼ + stars: | 2023-08-30 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Fluence Energy could be a winner in the renewable energy transition, according to Barclays. Fluence Energy provides "energy storage technology solutions, delivering hardware along with advanced tech/AI-powered services to optimize the storage assets — either from a revenue-generating perspective and/or an O & M standpoint," Cho said in a Wednesday note. "Given the rapid expected buildout of renewables and the intermittency issues inherent in wind and solar projects, energy storage will be a key piece in the energy transition." The firm expects Fluence Energy to increase its revenue at a 46% compound annual growth rate between 2022 and 2025, which is double the firm's expectations for utility-scale solar companies. Cho also initiated energy storage network provider Stem with an equal-weight rating and $6 price target, which implies a 10.3% upside from Tuesday's close.

Persons: Christine Cho, Cho, — CNBC's Michael Bloom Organizations: Energy, Barclays, Fluence Energy, FLNC's Services Locations: 1H24

☆ Banks kicked off the last two weeks of July with higher rates on CDs. Where to find solid yields
▼ + stars: | 2023-08-01 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +1 min

Good news for income-centric investors: Higher yields in the certificate of deposit market will continue through the remainder of 2023. Banks hiked rates on CDs through the last two weeks of July, with the average one-to-12-month rate rising by 11 basis points to 4.6%, according to Morgan Stanley analyst Betsy Graseck. See below for some of the institutions in Morgan Stanley's coverage that are also offering attractive rates. Graseck noted that over the past two weeks, rates on CDs in the 13-to-36-month range have fallen by 4 basis points. "We also expect banks to continue shortening the duration of their highest CD offers to position for a potential Fed rate cut in 1H24," she wrote.

Persons: Banks, Morgan Stanley, Betsy Graseck, AXP, Graseck, — CNBC's Michael Bloom Organizations: DFS, Morgan Locations: 1H24

Search resuls for: "1H24"

19 mentions found